"Founded in 2007, The Oncology Institute of Hope and Innovation is dedicated to excel in cancer prevention, diagnosis and education. As the largest private practice cancer center in California, The Oncology Institute continues to provide extensive services including state-of-the-art infusion centers, chemotherapy educational sessions, in-house support groups, dietary and nutritional counseling, in-house pharmacy, financial counseling, clinical trials, comprehensive lab testing, and end of life counseling."

During the past decade, The Oncology Institute of Hope and Innovation conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 3 clinical trials were completed, i.e. on average, 42.9% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 2 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "The Oncology Institute of Hope and Innovation" #1 sponsor was "Pfizer" with 2 trials, followed by "ALX Oncology Inc." with 1 trials sponsored, "Boehringer Ingelheim" with 1 trials sponsored, "Daiichi Sankyo, Inc." with 1 trials sponsored and "Hoffmann-La Roche" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "The Oncology Institute of Hope and Innovation" #1 collaborator was "AstraZeneca" with 1 trials as a collaborator, "Chugai Pharmaceutical" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator, "German Breast Group" with 1 trials as a collaborator and "NSABP Foundation Inc" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "The Oncology Institute of Hope and Innovation" are "Colorectal Neoplasms" (1 trials), "Follicular Lymphoma" (1 trials), "Gastric Adenocarcinoma" (1 trials), "Gastric Cancer" (1 trials) and "Gastroesophageal Junction Adenocarcinoma" (1 trials). Many other conditions were trialed in "The Oncology Institute of Hope and Innovation" in a lesser frequency.

Most popular intervention types in "The Oncology Institute of Hope and Innovation" are "Drug" (6 trials), "Biological" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Avastin" (1 trials), "Avelumab" (1 trials), "BI 695502" (1 trials), "Cetuximab" (1 trials) and "Chemoradiation" (1 trials). Other intervention names were less common.

The vast majority of trials in "The Oncology Institute of Hope and Innovation" are 7 trials for "All" genders.

Currently, there are NaN active trials in "The Oncology Institute of Hope and Innovation". undefined are not yet recruiting, 4 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in The Oncology Institute of Hope and Innovation, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in The Oncology Institute of Hope and Innovation, 1 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".